Tirzepatide 15 mg significantly reduces HbA1c, weight, and waist in early Type 2 Diabetes.
Background
Despite initial treatment with metformin, Type 2 diabetes (T2D) often progresses, leading to inadequate glycemic control and increased risk of complications. Current guidelines for intensifying treatment typically involve sequential additions of agents, which may not achieve optimal or durable glycemic control. There's a critical need for therapies that can establish better and more sustained metabolic improvements, particularly when initiated early in the disease course. Dual agonists targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, like tirzepatide, offer a promising mechanism to address these gaps by enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Study Design
This randomized, open-label, parallel-group, phase 4 SURPASS-EARLY trial enrolled 794 adults with a T2D history of at most 4 years, who had inadequate glycemic control despite metformin treatment. Participants were randomized to receive either Tirzepatide 15 mg once-weekly (or maximum tolerated dose) or intensified conventional care (ICC), which included other GLP-1RAs but excluded tirzepatide, following local guidelines. The study duration was 2 years. The primary objective was to demonstrate noninferiority, then superiority, of tirzepatide to ICC for the change in hemoglobin A1c (HbA1c) from baseline. Secondary objectives included changes in weight and waist circumference.
Results
Over 2 years, Tirzepatide proved superior to ICC across all primary and key secondary endpoints. Mean HbA1c reduction from baseline was significantly greater with Tirzepatide at -1.99 percentage points (95% CI, -2.12 to -1.87) compared to ICC at -1.32 percentage points (CI, -1.44 to -1.19), resulting in an estimated treatment difference (ETD) of -0.68 percentage points (CI, -0.84 to -0.51; P < 0.001). This demonstrates robust glycemic control.
Tirzepatide also achieved superior weight reduction, with an ETD of -8.0 kg (CI, -9.39 to -6.50 kg; P < 0.001), and a greater decrease in waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001). Furthermore, a substantially higher proportion of participants achieved normoglycemia (
HbA1c <5.7%) with Tirzepatide (60.2%) compared to ICC (24.0%). Gastrointestinal adverse events were the most common, observed in both treatment groups.
Why It Matters
Early intervention with tirzepatide offers significantly better and more durable glycemic control, weight loss, and waist circumference reduction than current standard-of-care intensification strategies in early T2D. This finding suggests a paradigm shift, advocating for the earlier use of highly effective dual GIP/GLP-1 agonists to potentially alter the disease trajectory, rather than waiting for progression. For individuals managing early T2D, this could mean achieving normoglycemia more frequently and sustaining it longer, reducing long-term complications. While the 15 mg dose was used, the "maximum tolerated dose" protocol indicates flexibility. This study reinforces the potential for Tirzepatide to be a foundational therapy earlier in the T2D management algorithm, moving beyond its current role as a later-line agent.